Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Differential Distribution of microRNAs in Breast Cancer Grouped by Clinicopathological Subtypes

  • Li, Jian-Yi (Department of Breast Surgery, Shengjing Hospital of China Medical University) ;
  • Jia, Shi (Department of Breast Surgery, Shengjing Hospital of China Medical University) ;
  • Zhang, Wen-Hai (Department of Breast Surgery, Shengjing Hospital of China Medical University) ;
  • Zhang, Yang (Department of Breast Surgery, Shengjing Hospital of China Medical University) ;
  • Kang, Ye (Department of Breast Surgery, Shengjing Hospital of China Medical University) ;
  • Li, Pi-Song (Department of Breast Surgery, Shengjing Hospital of China Medical University)
  • Published : 2013.05.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: microRNAs (miRNAs) that regulate proliferation, invasion and metastasis are considered to be the principal molecular basis of tumor heterogeneity. Breast cancer is not a homogeneous tissue. Thus, it is very important to perform microarray-based miRNA screening of tumors at different sites. Methods: Breast tissue samples from the centers and edges of tumors of 30 patients were classified into 5 clinicopathological subtypes. In each group, 6 specimens were examined by microRNA array. All differential miRNAs were analyzed between the edges and centers of the tumors. Results: Seventeen kinds of miRNAs were heterogeneously distributed in the tumors from different clinicopathological subtypes that included 1 kind of miRNA in Luminal A and Luminal B Her2+ subtypes, 4 kinds in Luminal A and Her2 overexpression subtypes, 6 kinds in Luminal B Ki67+ and Luminal B Her2+ subtypes, 2 kinds between Luminal B Ki67+ and triple-negative breast cancer (TNBC) subtypes, 2 kinds between Luminal B Her2+ and TNBC subtypes, and 2 kinds between Luminal B Ki67+, Luminal B Her2+, and TNBC subtypes. Twenty kinds of miRNAs were homogenously distributed in the tumors from different clinicopathological subtypes that included 6 kinds of miRNAs in Luminal B Ki67+ and Luminal B Her2+ subtypes, 1 kind in Luminal B Ki67+ and Her2 overexpression subtypes, 10 kinds between Luminal B Ki67+ and TNBC subtypes, 2 kinds in Luminal B Her2+ and TNBC subtypes, and 1 kind between Luminal B Ki67+, Luminal B Her2+, and TNBC subtypes. Conclusions: A total of 37 miRNAs were significantly distributed in tumors from the centers to edges, and in all clinicopathological subtypes.

Keywords

References

  1. Aihara M, Wheeler TM, Ohori M, et al (1994) Heterogeneity of prostate cancer in radical prostatectomy specimens. Urology, 43, 60-6 https://doi.org/10.1016/S0090-4295(94)80264-5
  2. Balsat C, Blacher S, Signolle N, et al (2011). Whole slide quantification of stromal lymphatic vessel distribution and peritumoral lymphatic vessel density in early invasive cervical cancer: a method description. ISRN Obstet Gynecol, 25, 1-7.
  3. Caporali A, Emanueli C (2011). MicroRNA regulation in angiogenesis. Vascul Pharmacol, 55, 79-86. https://doi.org/10.1016/j.vph.2011.06.006
  4. Cheng C, Fu X, Alves P, et al (2009). mRNA expression profiles show differential regulatory effects of microRNAs between estrogen receptor-positive and estrogen receptor-negative breast cancer. Genome Biol, 10, R90. https://doi.org/10.1186/gb-2009-10-9-r90
  5. Choudhry H, Catto JW (2011). Epigenetic regulation of microRNA expression in cancer. Methods Mol Biol, 676, 165-84. https://doi.org/10.1007/978-1-60761-863-8_12
  6. Cortes-Sempere M, Ibanez de Caceres I (2011). microRNAs as novel epigenetic biomarkers for human cancer. Clin Transl Oncol, 13, 357-62 https://doi.org/10.1007/s12094-011-0668-z
  7. Goldhirsch A, Wood WC, Coates AS, et al (2011). Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol, 22, 1736-47. https://doi.org/10.1093/annonc/mdr304
  8. Hughes DP (2009). How the NOTCH pathway contributes to the ability of osteosarcoma cells to metastasize. Cancer Treat Res, 152, 479-96 https://doi.org/10.1007/978-1-4419-0284-9_28
  9. Iorio MV, Ferracin M, Liu CG, et al (2005). MicroRNA gene expression deregulation in human breast cancer. Cancer Res, 65, 7065-70 https://doi.org/10.1158/0008-5472.CAN-05-1783
  10. Juan HF, Huang HC (2007). Bioinformatics: microarray data clustering and functional classification. Methods Mol Biol, 382, 405-16. https://doi.org/10.1007/978-1-59745-304-2_25
  11. Kitadai Y, Ellis LM, Takahashi Y, et al (1995). Multiparametric in situ messenger RNA hybridization analysis to detect metastasis-related genes in surgical specimens of human colon carcinomas. Clin Cancer Res, 1, 1095-102.
  12. Kreiner T, Buck KT (2005). Moving toward whole-genome analysis: a technology perspective. Am J Health Syst Pharm, 62, 296-305.
  13. Krishna MC, Matsumoto S, Yasui H, et al (2012). Electron paramagnetic resonance imaging of tumor $pO_{2}$. Radiat Res, 177, 376-86 https://doi.org/10.1667/RR2622.1
  14. Li JY, Zhang Y, Zhang WH, et al (2012). Differential distribution of miR-20a and miR-20b may underly metastatic heterogeneity of breast cancers. Asian Pac J Cancer Prev, 13, 1901-6. https://doi.org/10.7314/APJCP.2012.13.5.1901
  15. Orlando PA, Gatenby RA, Brown JS (2013). Tumor evolution in space: the effects of competition colonization tradeoffs on tumor invasion dynamics. Front Oncol, 3, 45.
  16. Pritchard CC, Cheng HH, Tewari M (2012). MicroRNA profiling: approaches and considerations. Nat Rev Genet, 13, 358-69.
  17. Stransky B, de Souza SJ (2012). Modeling tumor evolutionary dynamics. Front Physiol, 3, 480.
  18. Teixeira MR, Heim S (2011). Cytogenetic analysis of tumor clonality. Adv Cancer Res, 112, 127-49 https://doi.org/10.1016/B978-0-12-387688-1.00005-3
  19. Wilson DF, Cerniglia GJ (1992). Localization of tumors and evaluation of their state of oxygenation by phosphorescence imaging. Cancer Res, 52, 3988-93.

Cited by

  1. Down-regulation of miRNA-452 is Associated with Adriamycin-resistance in Breast Cancer Cells vol.15, pp.13, 2014, https://doi.org/10.7314/APJCP.2014.15.13.5137
  2. MiR-886-5p Inhibition Inhibits Growth and Induces Apoptosis of MCF7 Cells vol.15, pp.4, 2014, https://doi.org/10.7314/APJCP.2014.15.4.1511
  3. miR-374b-5p suppresses RECK expression and promotes gastric cancer cell invasion and metastasis vol.20, pp.46, 2014, https://doi.org/10.3748/wjg.v20.i46.17439
  4. MicroRNA expression and gene regulation drive breast cancer progression and metastasis in PyMT mice vol.18, pp.1, 2016, https://doi.org/10.1186/s13058-016-0735-z
  5. Molecular mechanisms underlying gliomas and glioblastoma pathogenesis revealed by bioinformatics analysis of microarray data vol.34, pp.11, 2017, https://doi.org/10.1007/s12032-017-1043-x
  6. MicroRNAs and Triple Negative Breast Cancer vol.14, pp.11, 2013, https://doi.org/10.3390/ijms141122202
  7. Differential microRNA expression in breast cancer with different onset age vol.13, pp.1, 2018, https://doi.org/10.1371/journal.pone.0191195
  8. miRNA in a multiomic context for diagnosis, treatment monitoring and personalized management of metastatic breast cancer vol.14, pp.18, 2018, https://doi.org/10.2217/fon-2018-0061